{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:22:39Z","timestamp":1780366959568,"version":"3.54.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04532-x","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:32:41Z","timestamp":1757493161000},"page":"1897-1915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment"],"prefix":"10.1007","volume":"399","author":[{"given":"Yilan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3165-5304","authenticated-orcid":false,"given":"Yanping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"4532_CR1","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/cancers13215510","volume":"13","author":"EM Anderson","year":"2021","unstructured":"Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A (2021) Advances in pancreatic ductal adenocarcinoma treatment. Cancers 13:5510","journal-title":"Cancers"},{"key":"4532_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14712598.2024.2357714","volume":"24","author":"H Andersson","year":"2024","unstructured":"Andersson H, Nyesiga B, Hermodsson T, Enell Smith K, H\u00e4gerbrand K, Lindstedt M, Ellmark P (2024) Next-generation CD40 agonists for cancer immunotherapy. Expert Opin Biol Ther 24:351\u2013363","journal-title":"Expert Opin Biol Ther"},{"key":"4532_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612\u20131616","journal-title":"Science"},{"key":"4532_CR4","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","volume":"19","author":"GL Beatty","year":"2013","unstructured":"Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH (2013) A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19:6286\u20136295","journal-title":"Clin Cancer Res"},{"key":"4532_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","volume":"149","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD (2015) Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6Clow F4\/80+ extratumoral macrophages. Gastroenterology 149:201\u2013210","journal-title":"Gastroenterology"},{"key":"4532_CR6","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-06-3963","volume":"67","author":"U Bharadwaj","year":"2007","unstructured":"Bharadwaj U, Li M, Zhang R, Chen C, Yao Q (2007) Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 67:5479\u20135488","journal-title":"Cancer Res"},{"key":"4532_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","volume":"19","author":"TN Bullock","year":"2022","unstructured":"Bullock TN (2022) CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol Immunol 19:14\u201322","journal-title":"Cell Mol Immunol"},{"key":"4532_CR8","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O\u2019Hara MH, Liudahl SM, Newcomb C (2021) Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res 27:4574\u20134586","journal-title":"Clin Cancer Res"},{"key":"4532_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2527","author":"E Calvo","year":"2019","unstructured":"Calvo E, Moreno V, Perets R, Yablonski-Peretz T, Fourneau N, Girgis S, Guo Y, Hellemans P, Hokey D, Pendas Franco N (2019) A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2527","journal-title":"J Clin Oncol"},{"key":"4532_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-7-93","volume":"7","author":"EL Carpenter","year":"2009","unstructured":"Carpenter EL, Mick R, R\u00fcter J, Vonderheide RH (2009) Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 7:1\u201310","journal-title":"J Transl Med"},{"key":"4532_CR11","doi-asserted-by":"publisher","first-page":"e1085147","DOI":"10.1080\/2162402X.2015.1085147","volume":"5","author":"GF Castino","year":"2016","unstructured":"Castino GF, Cortese N, Capretti G, Serio S, Di Caro G, Mineri R, Magrini E, Grizzi F, Cappello P, Novelli F (2016) Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology 5:e1085147","journal-title":"Oncoimmunology"},{"key":"4532_CR12","doi-asserted-by":"publisher","first-page":"611795","DOI":"10.3389\/fimmu.2021.611795","volume":"12","author":"D Catal\u00e1n","year":"2021","unstructured":"Catal\u00e1n D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguill\u00f3n JC, Aravena O (2021) Immunosuppressive mechanisms of regulatory B cells. Front Immunol 12:611795","journal-title":"Front Immunol"},{"key":"4532_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0070","volume":"2","author":"F Chowdhury","year":"2014","unstructured":"Chowdhury F, Johnson P, Glennie M, Williams A (2014) Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7\/4 phase i trial. Cancer Immunol Res 2:229\u2013240","journal-title":"Cancer Immunol Res"},{"key":"4532_CR14","unstructured":"Conroy R (2023) Mitazalimab\/chemotherapy yields positive responses in metastatic PDAC. Cancer Network"},{"key":"4532_CR15","doi-asserted-by":"crossref","unstructured":"De Coa\u00f1a YP, Smith KE, F\u00e4lt A, Fl\u00e4rdh M, Ellmark P, Cassier P, Van Laethem J-L, Carlsson M (2021) 537 OPTIMIZE-1, an open-label phase 1b\/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. BMJ Specialist J","DOI":"10.1136\/jitc-2021-SITC2021.537"},{"key":"4532_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3748\/wjg.v28.i11.1088","volume":"28","author":"FR Delvecchio","year":"2022","unstructured":"Delvecchio FR, Goulart MR, Fincham REA, Bombadieri M, Kocher HM (2022) B cells in pancreatic cancer stroma. World J Gastroenterol 28:1088","journal-title":"World J Gastroenterol"},{"key":"4532_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin\u2013cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49\u201359","journal-title":"Cancer Immunol Immunother"},{"key":"4532_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41698-023-00459-9","volume":"7","author":"D Digomann","year":"2023","unstructured":"Digomann D, Heiduk M, Reiche C, Gl\u00fcck J, Kahlert C, Mirtschink P, Klimova A, B\u00f6sch F, Tonn T, Gaedcke J (2023) Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. NPJ Precis Oncol 7:104","journal-title":"NPJ Precis Oncol"},{"key":"4532_CR19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers13061302","volume":"13","author":"D Djureinovic","year":"2021","unstructured":"Djureinovic D, Wang M, Kluger HM (2021) Agonistic CD40 antibodies in cancer treatment. Cancers 13:1302","journal-title":"Cancers"},{"key":"4532_CR20","doi-asserted-by":"publisher","first-page":"e14489","DOI":"10.1111\/cns.14489","volume":"30","author":"WW Duan","year":"2024","unstructured":"Duan WW, Yang LT, Liu J, Dai ZY, Wang ZY, Zhang H, Zhang X, Liang XS, Luo P, Zhang J (2024) A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosci Ther 30:e14489","journal-title":"CNS Neurosci Ther"},{"key":"4532_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/14712598.2021.1934446","volume":"21","author":"K Enell Smith","year":"2021","unstructured":"Enell Smith K, Deronic A, H\u00e4gerbrand K, Norl\u00e9n P, Ellmark P (2021) Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opin Biol Ther 21:1635\u20131646","journal-title":"Expert Opin Biol Ther"},{"key":"4532_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ccell.2021.09.007","volume":"39","author":"V Engelhard","year":"2021","unstructured":"Engelhard V, Conejo-Garcia JR, Ahmed R, Nelson BH, Willard-Gallo K, Bruno TC, Fridman WH (2021) B cells and cancer. Cancer Cell 39:1293\u20131296","journal-title":"Cancer Cell"},{"key":"4532_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.seminoncol.2010.09.002","volume":"37","author":"MM Ester Fonsatti","year":"2010","unstructured":"Ester Fonsatti MM, Altomonte M, Hersey P (2010) Biology and clinical applications of CD40 in cancer treatment. Semin Oncol 37:517\u2013523","journal-title":"Semin Oncol"},{"key":"4532_CR24","doi-asserted-by":"crossref","unstructured":"Farhangnia P, Mollazadeh Ghomi S, Mollazadehghomi S, Delbandi A-A (2023) Current clinical landscape of immunotherapeutic approaches in pancreatic cancer treatment. Gastrointestinal Cancers: An Interdisciplinary Approach. Springer","DOI":"10.1007\/16833_2023_163"},{"key":"4532_CR25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-020-02814-2","volume":"70","author":"EL Filbert","year":"2021","unstructured":"Filbert EL, Bj\u00f6rck PK, Srivastava MK, Bahjat FR, Yang X (2021) APX005m, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol Immunother 70:1853\u20131865","journal-title":"Cancer Immunol Immunother"},{"key":"4532_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/dmr-24-2","volume":"7","author":"S Firoozan","year":"2024","unstructured":"Firoozan S, Satpathy S, Shakiba M, King DA (2024) Recent advances in immunotherapy for pancreatic cancer: a narrative review. Dig Med Res 7:15\u201315","journal-title":"Dig Med Res"},{"key":"4532_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/pro.2881","volume":"25","author":"GW Foight","year":"2016","unstructured":"Foight GW, Keating AE (2016) Comparison of the peptide binding preferences of three closely related TRAF paralogs: TRAF2, TRAF3, and TRAF5. Protein Sci 25:1273\u20131289","journal-title":"Protein Sci"},{"key":"4532_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ni1421","volume":"8","author":"E Gallagher","year":"2007","unstructured":"Gallagher E, Enzler T, Matsuzawa A, Anzelon-Mills A, Otero D, Holzer R, Janssen E, Gao M, Karin M (2007) Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol 8:57\u201363","journal-title":"Nat Immunol"},{"key":"4532_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11033-024-09877-9","volume":"51","author":"SY Gan","year":"2024","unstructured":"Gan SY, Tye GJ, Chew AL, Lai NS (2024) Current development of Fc gamma receptors (Fc\u03b3Rs) in diagnostics: a review. Mol Biol Rep 51:937","journal-title":"Mol Biol Rep"},{"key":"4532_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12943-023-01813-y","volume":"22","author":"SK Gautam","year":"2023","unstructured":"Gautam SK, Batra SK, Jain M (2023) Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. Mol Cancer 22:118","journal-title":"Mol Cancer"},{"key":"4532_CR31","doi-asserted-by":"publisher","first-page":"1258538","DOI":"10.3389\/fimmu.2023.1258538","volume":"14","author":"J Guo","year":"2023","unstructured":"Guo J, Wang S, Gao Q (2023) An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer. Front Immunol 14:1258538","journal-title":"Front Immunol"},{"key":"4532_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1074\/jbc.M111.285122","volume":"287","author":"A Hamidi","year":"2012","unstructured":"Hamidi A, Von Bulow V, Hamidi R, Winssinger N, Barluenga S, Heldin C-H, Landstr\u00f6m M (2012) Polyubiquitination of transforming growth factor \u03b2 (TGF\u03b2)-associated kinase 1 mediates nuclear factor-\u03baB activation in response to different inflammatory stimuli. J Biol Chem 287:123\u2013133","journal-title":"J Biol Chem"},{"key":"4532_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm14041129","volume":"14","author":"U Hayat","year":"2025","unstructured":"Hayat U, Croce PS, Saadeh A, Desai K, Appiah J, Khan S, Khan YI, Kumar K, Hanif A (2025) Current and emerging treatment options for pancreatic cancer: a comprehensive review. J Clin Med 14:1129","journal-title":"J Clin Med"},{"key":"4532_CR34","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.18632\/oncotarget.2972","volume":"6","author":"GM Heestand","year":"2015","unstructured":"Heestand GM, Kurzrock R (2015) Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget 6:4553","journal-title":"Oncotarget"},{"key":"4532_CR35","unstructured":"Hesen NA (2023) The importance of antibody isotype and idiotype in Fc\u03b3R-dependent agonism induced by anti-CD40 antibodies, Bayerische Julius-Maximilians-Universitaet Wuerzburg (Germany)."},{"key":"4532_CR36","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3390\/ijms21197307","volume":"21","author":"M Huber","year":"2020","unstructured":"Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, Pogge Von Strandmann E, Slater EP, Bartsch JW, Bauer C, Lauth M (2020) The immune microenvironment in pancreatic cancer. Int J Mol Sci 21:7307","journal-title":"Int J Mol Sci"},{"key":"4532_CR37","doi-asserted-by":"publisher","first-page":"e137263","DOI":"10.1172\/jci.insight.137263","volume":"5","author":"AP Huffman","year":"2020","unstructured":"Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH (2020) CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight 5:e137263","journal-title":"JCI Insight"},{"key":"4532_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","volume":"20","author":"J-E Jang","year":"2017","unstructured":"Jang J-E, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D (2017) Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep 20:558\u2013571","journal-title":"Cell Rep"},{"key":"4532_CR39","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","volume":"21","author":"P Johnson","year":"2015","unstructured":"Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, Chan C, Smith A, Steven N (2015) Clinical and biological effects of an agonist anti-CD40 antibody: a cancer research UK phase i study. Clin Cancer Res 21:1321\u20131328","journal-title":"Clin Cancer Res"},{"key":"4532_CR40","doi-asserted-by":"publisher","first-page":"547589","DOI":"10.3389\/fimmu.2020.01393","volume":"11","author":"F Junker","year":"2020","unstructured":"Junker F, Gordon J, Qureshi O (2020) Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation. Front Immunol 11:547589","journal-title":"Front Immunol"},{"key":"4532_CR41","doi-asserted-by":"crossref","unstructured":"Karamitopoulou E (2020) The tumor microenvironment of pancreatic cancer.\u00a0Cancers (Basel) 12:3076","DOI":"10.3390\/cancers12103076"},{"key":"4532_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1073\/pnas.1902145116","volume":"117","author":"AS Kashyap","year":"2020","unstructured":"Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M, Ooi C-H, Kreuzaler M, Hirschmann P, Guichard A (2020) Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proc Natl Acad Sci U S A 117:541\u2013551","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4532_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.uct.2007.06.001","volume":"2","author":"M Khalil","year":"2007","unstructured":"Khalil M, Vonderheide RH (2007) Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther 2:61\u201365","journal-title":"Update Cancer Ther"},{"key":"4532_CR44","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00262-014-1554-7","volume":"63","author":"M Kobayashi","year":"2014","unstructured":"Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S-I, Yusa S (2014) Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother 63:797\u2013806","journal-title":"Cancer Immunol Immunother"},{"key":"4532_CR45","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","volume":"36","author":"HM Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP, Chung M (2023) Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg 36:2129884","journal-title":"J Invest Surg"},{"key":"4532_CR46","doi-asserted-by":"crossref","unstructured":"Lau SP, Van Montfoort N, Kinderman P, Lukkes M, Klaase L, Van Nimwegen M, Van Gulijk M, Dumas J, Mustafa DA, Lievense SL (2020) Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer 8:e000772","DOI":"10.1136\/jitc-2020-000772"},{"key":"4532_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/2159-8290.CD-15-0822","volume":"6","author":"KE Lee","year":"2016","unstructured":"Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, Vonderheide RH, Simon MC (2016) Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia. Cancer Discov 6:256\u2013269","journal-title":"Cancer Discov"},{"key":"4532_CR48","doi-asserted-by":"crossref","unstructured":"Li R, Luo P, Guo Y, He Y, Wang C (2024) Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis. Exp Opin Drug Saf 4:1\u20135","DOI":"10.1080\/14740338.2024.2396387"},{"key":"4532_CR49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5009\/gnl210311","volume":"16","author":"CY Lim","year":"2021","unstructured":"Lim CY, Chang JH, Lee WS, Kim J, Park IY (2021) CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures. Gut and Liver 16:645","journal-title":"Gut and Liver"},{"key":"4532_CR50","doi-asserted-by":"crossref","unstructured":"Lindstedt M, Ellmark P, Sobti A, Smith KE, De Coa\u00f1a YP, Ambarkhane S (2022) 35 Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody. BMJ Special J","DOI":"10.1136\/jitc-2022-SITC2022.0035"},{"key":"4532_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-016-0378-2","volume":"17","author":"Q Liu","year":"2017","unstructured":"Liu Q, Liao Q, Zhao Y (2017) Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 17:1\u201317","journal-title":"Cancer Cell Int"},{"key":"4532_CR52","doi-asserted-by":"publisher","first-page":"2206873","DOI":"10.1002\/advs.202206873","volume":"10","author":"HC Liu","year":"2023","unstructured":"Liu HC, Davila Gonzalez D, Viswanath DI, Vander Pol RS, Saunders SZ, Di Trani N, Xu Y, Zheng J, Chen SH, Chua CYX (2023a) Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer. Adv Sci 10:2206873","journal-title":"Adv Sci"},{"key":"4532_CR53","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","volume":"24","author":"P-S Liu","year":"2023","unstructured":"Liu P-S, Chen Y-T, Li X, Hsueh P-C, Tzeng S-F, Chen H, Shi P-Z, Xie X, Parik S, Planque M (2023b) CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat Immunol 24:452\u2013462","journal-title":"Nat Immunol"},{"key":"4532_CR54","doi-asserted-by":"publisher","first-page":"14717","DOI":"10.3748\/wjg.v20.i40.14717","volume":"20","author":"WS Loc","year":"2014","unstructured":"Loc WS, Smith JP, Matters G, Kester M, Adair JH (2014) Novel strategies for managing pancreatic cancer. World J Gastroenterol: WJG 20:14717","journal-title":"World J Gastroenterol: WJG"},{"key":"4532_CR55","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41598-025-85444-x","volume":"15","author":"F Luan","year":"2025","unstructured":"Luan F, Cui Y, Huang R, Yang Z, Qiao S (2025) Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM. Sci Rep 15:3223","journal-title":"Sci Rep"},{"key":"4532_CR56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers13030433","volume":"13","author":"V Lucarini","year":"2021","unstructured":"Lucarini V, Melaiu O, Tempora P, D\u2019amico S, Locatelli F, Fruci D (2021) Dendritic cells: behind the scenes of T-cell infiltration into the tumor microenvironment. Cancers 13:433","journal-title":"Cancers"},{"key":"4532_CR57","doi-asserted-by":"publisher","first-page":"18508","DOI":"10.18632\/oncotarget.7610","volume":"7","author":"NM Luheshi","year":"2016","unstructured":"Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M (2016a) Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 7:18508","journal-title":"Oncotarget"},{"key":"4532_CR58","doi-asserted-by":"crossref","unstructured":"Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW (2016b) Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 7:18508-18520","DOI":"10.18632\/oncotarget.7610"},{"key":"4532_CR59","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10637-024-01452-0","volume":"42","author":"P Luo","year":"2024","unstructured":"Luo P, Guo Y, He Y, Wang C (2024) Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis. Invest New Drugs 42:369\u2013375","journal-title":"Invest New Drugs"},{"key":"4532_CR60","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","volume":"7","author":"HS Ma","year":"2019","unstructured":"Ma HS, Poudel B, Torres ER, Sidhom J-W, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ (2019) A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell\u2013mediated anticancer activity. Cancer Immunol Res 7:428\u2013442","journal-title":"Cancer Immunol Res"},{"key":"4532_CR61","doi-asserted-by":"publisher","first-page":"e24891","DOI":"10.4161\/onci.24891","volume":"2","author":"TA Mace","year":"2013","unstructured":"Mace TA, Bloomston M, Lesinski GB (2013) Pancreatic cancer-associated stellate cells: a viable target for reducing immunosuppression in the tumor microenvironment. Oncoimmunology 2:e24891","journal-title":"Oncoimmunology"},{"key":"4532_CR62","doi-asserted-by":"publisher","first-page":"e001153","DOI":"10.1136\/jitc-2020-001153","volume":"8","author":"J-P Machiels","year":"2020","unstructured":"Machiels J-P, Gomez-Roca C, Michot J-M, Zamarin D, Mitchell T, Catala G, Eberst L, Jacob W, Jegg A-M, Cannarile MA (2020) Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J Immunother Cancer 8:e001153","journal-title":"J Immunother Cancer"},{"key":"4532_CR63","doi-asserted-by":"crossref","unstructured":"Mancardi D, Da\u00ebron M (2014) Fc receptors in immune responses. Reference Module in Biomedical Sciences\u00a028:B978\u20130\u201312\u2013801238\u20133.00119\u20137","DOI":"10.1016\/B978-0-12-801238-3.00119-7"},{"key":"4532_CR64","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","volume":"21","author":"SM Mangsbo","year":"2015","unstructured":"Mangsbo SM, Broos S, Fletcher E, Veitonm\u00e4ki N, Furebring C, Dahl\u00e9n E, Norl\u00e9n P, Lindstedt M, T\u00f6tterman TH, Ellmark P (2015) The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell\u2013dependent tumor immunity. Clin Cancer Res 21:1115\u20131126","journal-title":"Clin Cancer Res"},{"key":"4532_CR65","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.21873\/anticanres.10991","volume":"36","author":"Y Matsumura","year":"2016","unstructured":"Matsumura Y, Hiraoka K, Ishikawa K, Shoji Y, Noji T, Hontani K, Itoh T, Nakamura T, Tsuchikawa T, Shichinohe T (2016) CD40 expression in human esophageal squamous cell carcinoma is associated with tumor progression and lymph node metastasis. Anticancer Res 36:4467\u20134475","journal-title":"Anticancer Res"},{"key":"4532_CR66","doi-asserted-by":"crossref","unstructured":"Maurer D, Yu JX, Sklodowski K, Tognetti M, Reiter L, Bruderer R, Vowinckel J, Pfeiffer S, O\u2019Hara M, O\u2019Reilly E (2021) 343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer. BMJ Special J","DOI":"10.1136\/jitc-2021-SITC2021.343"},{"key":"4532_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","volume":"41","author":"V Moreno","year":"2023","unstructured":"Moreno V, Perets R, Peretz-Yablonski T, Fourneau N, Girgis S, Guo Y, Hellemans P, Verona R, Pend\u00e1s N, Xia Q (2023) A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs 41:93\u2013104","journal-title":"Invest New Drugs"},{"key":"4532_CR68","doi-asserted-by":"publisher","first-page":"117430","DOI":"10.1016\/j.biopha.2024.117430","volume":"179","author":"R Ni","year":"2024","unstructured":"Ni R, Hu Z, Tao R (2024) Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer. Biomed Pharmacother 179:117430","journal-title":"Biomed Pharmacother"},{"key":"4532_CR69","doi-asserted-by":"crossref","unstructured":"O\u2019Hara MH, O'Reilly EM, Rosemarie M, Varadhachary G, Wainberg ZA, KO A, Fisher GA, Rahma O, Lyman JP, Cabanski CR (2019) A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Cancer Res 79:CT004","DOI":"10.1158\/1538-7445.AM2019-CT004"},{"key":"4532_CR70","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2015.00563","volume":"6","author":"R Obst","year":"2015","unstructured":"Obst R (2015) The timing of T cell priming and cycling. Front Immunol 6:563","journal-title":"Front Immunol"},{"key":"4532_CR71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","volume":"22","author":"MH O'Hara","year":"2021","unstructured":"O\u2019Hara MH, O\u2019Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR (2021) CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol 22:118\u2013131","journal-title":"Lancet Oncol"},{"key":"4532_CR72","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, Maurer DM, O\u2019Hara MH, O\u2019Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, X J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O\u2019Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, Lavallee TM, Vonderheide RH (2022) Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med 28:1167\u20131177","journal-title":"Nat Med"},{"key":"4532_CR73","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"L Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n L, Maurer D, O\u2019Hara M, O\u2019Reilly E, Wolff R, Wainberg Z, Ko A, Fisher G, Rahma O, Lyman J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH (2022a) Sotigalimab and\/or nivolumab with chemotherapy in rst-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med 28:1167\u20131177","journal-title":"Nat Med"},{"key":"4532_CR74","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, Maurer DM, O\u2019Hara MH, O\u2019Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP (2022b) Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med 28:1167\u20131177","journal-title":"Nat Med"},{"key":"4532_CR75","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/2159-8290.CD-15-0671","volume":"5","author":"RM Perera","year":"2015","unstructured":"Perera RM, Bardeesy N (2015) Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov 5:1247\u20131261","journal-title":"Cancer Discov"},{"key":"4532_CR76","doi-asserted-by":"crossref","unstructured":"Piechutta M, Berghoff AS (2019) New emerging targets in cancer immunotherapy: the role of cluster of differentiation 40 (CD40\/TNFR5). Esmo Open 4:e000684","DOI":"10.1136\/esmoopen-2019-000510"},{"key":"4532_CR77","doi-asserted-by":"crossref","unstructured":"Prenen H, Borbath I, Geboes KP, Cassier PA, Lambert A, Mitry E, Macarulla T, Taieb J, Blanc J-F, Feliu Batlle J (2023) Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b\/2 study. Am Soc Clin Oncol","DOI":"10.1200\/JCO.2023.41.16_suppl.4139"},{"key":"4532_CR78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/2159-8290.CD-15-0843","volume":"6","author":"Y Pylayeva-Gupta","year":"2016","unstructured":"Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, Bar-Sagi D (2016) IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov 6:247\u2013255","journal-title":"Cancer Discov"},{"key":"4532_CR79","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s002620050608","volume":"49","author":"MS Sabel","year":"2000","unstructured":"Sabel MS, Yamada M, Kawaguchi Y, Chen F-A, Takita H, Bankert RB (2000) CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother 49:101\u2013108","journal-title":"Cancer Immunol Immunother"},{"key":"4532_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69\u201374","journal-title":"Science"},{"key":"4532_CR81","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/cancers17081319","volume":"17","author":"A Shenoy","year":"2025","unstructured":"Shenoy A, Yousif A, Hussain MD (2025) Recent advances and challenges in the treatment of advanced pancreatic cancer: an update on completed and ongoing clinical trials. Cancers 17:1319","journal-title":"Cancers"},{"key":"4532_CR82","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL (2023) Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol Mech Dis 18:123\u2013148","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"4532_CR83","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"4532_CR84","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fimmu.2012.00372","volume":"3","author":"VJ Sindhava","year":"2012","unstructured":"Sindhava VJ, Bondada S (2012) Multiple regulatory mechanisms control B-1 B cell activation. Front Immunol 3:372","journal-title":"Front Immunol"},{"key":"4532_CR85","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.3390\/cancers14174209","volume":"14","author":"N Skorupan","year":"2022","unstructured":"Skorupan N, Palestino Dominguez M, Ricci SL, Alewine C (2022) Clinical strategies targeting the tumor microenvironment of pancreatic ductal adenocarcinoma. Cancers (Basel) 14:4209","journal-title":"Cancers (Basel)"},{"key":"4532_CR86","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/1538-7445.AM2024-2376","volume":"84","author":"KE Smith","year":"2024","unstructured":"Smith KE, Jimenez DG, Thagesson M, Nilsson A, De Coa\u00f1a YP, Ambarkhane S, Ellmark P (2024) Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model. Cancer Res 84:2376\u20132376","journal-title":"Cancer Res"},{"key":"4532_CR87","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","volume":"63","author":"IM Stromnes","year":"2014","unstructured":"Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769\u20131781","journal-title":"Gut"},{"key":"4532_CR88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"S-C Sun","year":"2011","unstructured":"Sun S-C (2011) Non-canonical NF-\u03baB signaling pathway. Cell Res 21:71\u201385","journal-title":"Cell Res"},{"key":"4532_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.144444","author":"W Sun","year":"2025","unstructured":"Sun W, Jang M-S, Zhan S, Liu C, Sheng L, Lee JH, Fu Y, Yang HY (2025) Tumor-targeting and redox-responsive photo-cross-linked nanogel derived from multifunctional hyaluronic acid-lipoic acid conjugates for enhanced in vivo protein delivery. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.144444","journal-title":"Int J Biol Macromol"},{"key":"4532_CR90","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","volume":"219","author":"T Tang","year":"2021","unstructured":"Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H (2021) Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol Ther 219:107709","journal-title":"Pharmacol Ther"},{"key":"4532_CR91","doi-asserted-by":"publisher","first-page":"1182803","DOI":"10.3389\/fphar.2023.1182803","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Wang Y, Gong X, Xiang J, Zhang Y, Xiang Q, Li J (2023) Integrated transcriptome and metabolome analysis to investigate the mechanism of intranasal insulin treatment in a rat model of vascular dementia. Front Pharmacol 14:1182803","journal-title":"Front Pharmacol"},{"key":"4532_CR92","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.3390\/ijms23137066","volume":"23","author":"J Thomas","year":"2022","unstructured":"Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B (2022) The neonatal Fc receptor is elevated in monocyte-derived immune cells in pancreatic cancer. Int J Mol Sci 23:7066","journal-title":"Int J Mol Sci"},{"key":"4532_CR93","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.seminoncol.2019.10.004","volume":"46","author":"O Uher","year":"2019","unstructured":"Uher O, Hansen VC, Hansen P, Kopecky J, Chmelar J, Zhuang Z, Zenka J, Pacak K (2019) Coley\u2019s immunotherapy revived: innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Semin Oncol 46:385\u2013392","journal-title":"Semin Oncol"},{"key":"4532_CR94","doi-asserted-by":"crossref","unstructured":"Van Audenaerde JR, Marcq E, Von Scheidt B, Davey AS, Oliver AJ, De Waele J, Quatannens D, Van Loenhout J, Pauwels P, Roeyen G (2020) Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Clin Transl Immunol 9:e1165","DOI":"10.1002\/cti2.1165"},{"key":"4532_CR95","doi-asserted-by":"crossref","unstructured":"Van Laethem J-L, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc J-F, Pilla L, Batlle JF (2024) Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol 25:853\u2013864","DOI":"10.1016\/S1470-2045(24)00263-8"},{"key":"4532_CR96","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13105-022-00875-8","volume":"79","author":"RM Velasco","year":"2023","unstructured":"Velasco RM, Garc\u00eda AG, S\u00e1nchez PJ, Sellart IM, Sanchez-Arevalo Lobo VJ (2023) Tumour microenvironment and heterotypic interactions in pancreatic cancer. J Physiol Biochem 79:179\u2013192","journal-title":"J Physiol Biochem"},{"key":"4532_CR97","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00262-013-1427-5","volume":"62","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL (2013) CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62:949\u2013954","journal-title":"Cancer Immunol Immunother"},{"key":"4532_CR98","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nm976","volume":"10","author":"T Wang","year":"2004","unstructured":"Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48\u201354","journal-title":"Nat Med"},{"key":"4532_CR99","doi-asserted-by":"crossref","unstructured":"Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, Wang L, Liu Y, Zhao Y, Zhou W (2024) Tumor cell-targeting and tumor microenvironment\u2013responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer. Int J Nanomed 19:5837\u20135858","DOI":"10.2147\/IJN.S466042"},{"key":"4532_CR100","doi-asserted-by":"crossref","unstructured":"Wattenberg MM, Herrera VM, Giannone MA, Gladney WL, Carpenter EL, Beatty GL (2021) Systemic inflammation is a determinant of outcomes of CD40 agonist\u2013based therapy in pancreatic cancer patients. JCI Insight 6:e145389","DOI":"10.1172\/jci.insight.145389"},{"key":"4532_CR101","doi-asserted-by":"crossref","unstructured":"Wattenberg MM, Smith KE, De Coana YP, Jimenez DG, Carlsson M, Ambarkhane SV, Ellmark P, Beatty GL (2024) Interim pharmacodynamic analyses of mitazalimab in combination with FOLFIRINOX in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) identify CD4 effector T cells as a correlate of treatment outcomes. Cancer Research. Amer Assoc Cancer Research 615 Chestnut St, 17th floor, Philadelphia, PA","DOI":"10.1158\/1538-7445.PANCA2023-C038"},{"key":"4532_CR102","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41598-025-86664-x","volume":"15","author":"X Xinyu","year":"2025","unstructured":"Xinyu X, Jiang Z, Qing A, Lihua L, Xiehong L, Lin Z (2025) Clinical significance of PCT, CRP, IL-6, NLR, and TyG index in early diagnosis and severity assessment of acute pancreatitis: a retrospective analysis. Sci Rep 15:2924","journal-title":"Sci Rep"},{"key":"4532_CR103","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV (2020) Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol 11:1371","journal-title":"Front Immunol"},{"key":"4532_CR104","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2020.10.029","volume":"498","author":"J Yang","year":"2021","unstructured":"Yang J, Li Y, Sun Z, Zhan H (2021a) Macrophages in pancreatic cancer: an immunometabolic perspective. Cancer Lett 498:188\u2013200","journal-title":"Cancer Lett"},{"key":"4532_CR105","doi-asserted-by":"publisher","first-page":"607209","DOI":"10.3389\/fcell.2020.607209","volume":"8","author":"S Yang","year":"2021","unstructured":"Yang S, Liu Q, Liao Q (2021b) Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming. Front Cell Dev Biol 8:607209","journal-title":"Front Cell Dev Biol"},{"key":"4532_CR106","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.jconrel.2025.113664","volume":"382","author":"J Yang","year":"2025","unstructured":"Yang J, Zhu J, Lu S, Qin H, Zhou W (2025) Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering. J Control Release 382:113664","journal-title":"J Control Release"},{"key":"4532_CR107","doi-asserted-by":"crossref","unstructured":"Yang J, Zhang Q, Wang J, Lou Y, Hong Z, Wei S, Sun K, Wang J, Chen Y, Sheng J (2022) Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine 78:103958","DOI":"10.1016\/j.ebiom.2022.103958"},{"key":"4532_CR108","doi-asserted-by":"crossref","unstructured":"Yao W, Maitra A, Ying H (2020) Recent insights into the biology of pancreatic cancer. EBioMedicine 53:102655","DOI":"10.1016\/j.ebiom.2020.102655"},{"key":"4532_CR109","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.275776.115","volume":"30","author":"H Ying","year":"2016","unstructured":"Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, Depinho RA (2016) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 30:355\u2013385","journal-title":"Genes Dev"},{"key":"4532_CR110","doi-asserted-by":"publisher","first-page":"e70045","DOI":"10.1002\/pon.70045","volume":"33","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu C, Chen X, Zhang Y, Li Y, Hu X (2024) Effects of web-based acceptance and commitment therapy on health-related outcomes among patients with lung cancer: a feasibility randomized controlled trial. Psychooncology 33:e70045","journal-title":"Psychooncology"},{"key":"4532_CR111","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fonc.2020.00382","volume":"10","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Tao X, Xia S, Guo F, Pan C, Xiang H, Shang D (2020) T lymphocytes: a promising immunotherapeutic target for pancreatitis and pancreatic cancer? Front Oncol 10:382","journal-title":"Front Oncol"},{"key":"4532_CR112","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","volume":"75","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Richmond A, Yan C (2024) Harnessing the potential of CD40 agonism in cancer therapy. Cytokine Growth Factor Rev 75:40\u201356","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04532-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:03:09Z","timestamp":1771552989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04532-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4532"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04532-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"It is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"It is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"It is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}